Stock Track | Phibro Animal Health Soars 10.68% on Strong Q2 Earnings Beat and Raised Guidance

Stock Track

Feb 05

Phibro Animal Health Corporation's stock soared 10.68% during the trading session, driven by the company's release of second-quarter financial results that significantly exceeded market expectations.

The animal health firm reported adjusted earnings per share of $0.87 for the quarter, beating the consensus estimate of $0.67 by 29.85%. Quarterly sales reached $373.9 million, surpassing estimates by 5.14% and representing a 20.89% increase compared to the same period last year. Adjusted EBITDA rose 41% to $68.1 million.

Furthermore, Phibro Animal Health raised its financial guidance for fiscal year 2026, now projecting net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million. The strong performance was attributed to faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings across key markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173513897"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173513897\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173513897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 09:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173513897","market":"sg","top_or_hot":-1,"title":"Stock Track | Phibro Animal Health Soars 10.68% on Strong Q2 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>Phibro Animal Health Corporation's stock soared 10.68% during the trading session, driven by the company's release of second-quarter financial results that significantly exceeded market expectations.</p><p>The animal health firm reported adjusted earnings per share of $0.87 for the quarter, beating the consensus estimate of $0.67 by 29.85%. Quarterly sales reached $373.9 million, surpassing estimates by 5.14% and representing a 20.89% increase compared to the same period last year. Adjusted EBITDA rose 41% to $68.1 million.</p><p>Furthermore, Phibro Animal Health raised its financial guidance for fiscal year 2026, now projecting net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million. The strong performance was attributed to faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings across key markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Phibro Animal Health Soars 10.68% on Strong Q2 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Phibro Animal Health Soars 10.68% on Strong Q2 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 09:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Phibro Animal Health Corporation's stock soared 10.68% during the trading session, driven by the company's release of second-quarter financial results that significantly exceeded market expectations.</p><p>The animal health firm reported adjusted earnings per share of $0.87 for the quarter, beating the consensus estimate of $0.67 by 29.85%. Quarterly sales reached $373.9 million, surpassing estimates by 5.14% and representing a 20.89% increase compared to the same period last year. Adjusted EBITDA rose 41% to $68.1 million.</p><p>Furthermore, Phibro Animal Health raised its financial guidance for fiscal year 2026, now projecting net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million. The strong performance was attributed to faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings across key markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PAHC","symbol_name":"Phibro Animal Health Corporation","start_time":0,"source_url":"","article_id":"1173513897","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173513897","pubTimestamp":1770253451,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Phibro Animal Health Corporation's stock soared 10.68% during the trading session, driven by the company's release of second-quarter financial results that significantly exceeded market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PAHC":"Phibro Animal Health Corporation"},"translate_title":"股票追踪|Phibro Animal Health因强劲的Q2盈利和上调指引而飙升10.68%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAHC":1},"content_text":"Phibro Animal Health Corporation's stock soared 10.68% during the trading session, driven by the company's release of second-quarter financial results that significantly exceeded market expectations.The animal health firm reported adjusted earnings per share of $0.87 for the quarter, beating the consensus estimate of $0.67 by 29.85%. Quarterly sales reached $373.9 million, surpassing estimates by 5.14% and representing a 20.89% increase compared to the same period last year. Adjusted EBITDA rose 41% to $68.1 million.Furthermore, Phibro Animal Health raised its financial guidance for fiscal year 2026, now projecting net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million. The strong performance was attributed to faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings across key markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}